Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 1,457 Shares

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,457 shares of Insmed stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total value of $100,125.04. Following the completion of the sale, the chief operating officer now directly owns 146,082 shares of the company’s stock, valued at $10,038,755.04. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total value of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total value of $161,181.80.

Insmed Stock Performance

Shares of Insmed stock opened at $72.75 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The business has a fifty day simple moving average of $71.20 and a two-hundred day simple moving average of $72.47. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the prior year, the company earned ($1.10) EPS. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. On average, research analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of INSM. Atomi Financial Group Inc. lifted its position in shares of Insmed by 6.6% in the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock worth $1,710,000 after buying an additional 1,526 shares in the last quarter. Park Avenue Securities LLC boosted its stake in shares of Insmed by 42.1% during the 4th quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock worth $549,000 after purchasing an additional 2,358 shares during the period. Capital CS Group LLC bought a new position in shares of Insmed during the fourth quarter valued at approximately $586,000. JCIC Asset Management Inc. lifted its holdings in Insmed by 40.7% during the 4th quarter. JCIC Asset Management Inc. now owns 2,560 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 740 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its holdings in shares of Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock worth $4,115,000 after buying an additional 41,918 shares during the period.

Analyst Ratings Changes

INSM has been the topic of a number of recent research reports. Truist Financial reissued a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Bank of America boosted their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. raised their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.